Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. (Q53921400)

22 May 2018

title

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. (English)

1 reference

22 May 2018

0 references

0 references

1 reference

E D Ehrenpreis

1

1 reference

22 May 2018

S V Kane

2

1 reference

22 May 2018

L B Cohen

3

1 reference

22 May 2018

R D Cohen

4

1 reference

22 May 2018

S B Hanauer

5

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 December 1999

1 reference

22 May 2018

published in

Gastroenterology

1 reference

22 May 2018

volume

117

1 reference

22 May 2018

page(s)

1271-1277

1 reference

22 May 2018

issue

6

1 reference

22 May 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Infliximab for the treatment of fistulas in patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide for the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Recalcitrant pyoderma gangrenosum: treatment with thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide in dermatology. New indications for an old drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Successful treatment of Behcet's syndrome in an African female patient with thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Cutaneous sarcoidosis successfully treated with low doses of thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide-induced neuropathy and genetic differences in drug metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970276-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(99)70276-3

1 reference

22 May 2018

PubMed ID

10579967

1 reference

22 May 2018